1. Inhibitory Antibodies

Inhibitory Antibodies

MCE Inhibitory Antibodies are monoclonal antibodies (mAbs) that have been extensively used in the hottest research areas, such as cancer, immunology and infection. These monoclonal antibodies (mAbs) bind monospecifically to certain cells or proteins, thus stimulating the immune system to attack the malignant tumor cells and preventing tumor growth by blocking specific cell receptors. They can inhibit PD-1, PD-L1, EGFR, VEGFR, TNF-alpha or other targets which are unusually active in diseases, such as non-Hodgkin lymphoma, Hemophilia A, renal cell carcinoma, Parkinson's disease and metastatic HER2-positive breast cancer. For example, by binding to VEGF, Bevacizumab prevents VEGF from interacting with its receptors, thereby inhibiting new vessel growth. Lambrolizumab targets the programmed cell death 1 (PD-1) receptor of lymphocytes. By preventing the binding of its ligands (PD-L1 and PD-L2), Lembrolizumab induces an antitumor immune response.

Inhibitory Antibodies (18):

Cat. No. Product Name Purity Concentration
  • HY-P9907
    Trastuzumab 99.30%
    Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.
  • HY-P9906
    Bevacizumab 98.50%
    Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
  • HY-P9905
    Cetuximab 99.70%
    Cetuximab is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for soluble EGFR by SPR. Cetuximab has potent antitumor activity.
  • HY-P9904
    Atezolizumab 98.98%
    Atezolizumab is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
  • HY-P9903
    Nivolumab 98.56%
    Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody to treat advanced (metastatic) non-small cell lung cancer.
  • HY-P9908
    Adalimumab 98.12%
    Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
  • HY-P9913
    Rituximab 99.85%
    Rituximab is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.
  • HY-P9902
    Pembrolizumab 99.06%
    Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
  • HY-P9912
    Pertuzumab 99.10%
    Pertuzumab, a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
  • HY-108730
    Avelumab >99.0%
    Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
  • HY-P9901
    Ipilimumab 99.88%
    Ipilimumab is a fully human monoclonal IgG1κ antibody against the cytotoxic T-lymphocyte antigen-4 (CTLA-4), an immune-inhibitory molecule expressed in activated T cells and in suppressor T regulatory cells.
  • HY-P9919
    Durvalumab 99.50%
    Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.
  • HY-P9917
    Tocilizumab
    Tocilizumab (Anti-Human IL6R) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R) is approved for the treatment of rheumatoid arthritis in Europe and the United States[1].
  • HY-P9911
    Vedolizumab
    Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
  • HY-P9909
    Ustekinumab 98.42%
    Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
  • HY-P9920
    Ramucirumab 99.40%
    Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D.
  • HY-P9900
    Human IgG1 Control
    Human IgG1 Control is purified from normal human serum through Protein G chromatography. Human IgG1 Control can be used as control, standard, blocking agent, or coating protein in a variety of assays, including ELISA, immunobloting (Western and Dot blots), immunoprecipitation, immunodiffusion, and immunoelectrophoresis. Human IgG1 Control may also be used as antigen or ligand in immunochemical conjugation reactions.
  • HY-P9910
    Obinutuzumab
    Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.